• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Majority of Physicians Fear Another Prescription Drug Crisis, Finds New Quest Diagnostics Health Trends™ Report

First-of-its-kind study shows nearly three in four physicians trust their patients to take controlled substances as prescribed, yet half of all patient test results show misuse of these drugs

Non-prescribed gabapentin use accelerating, growing 40% in past year, making it the most commonly detected non-prescribed controlled medication in tested patients

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

News provided by

Quest Diagnostics

Oct 16, 2019, 08:02 ET

Share this article

Share this article


SECAUCUS, N.J., Oct. 16, 2019 /PRNewswire/ -- Most primary care physicians (62%) fear the opioid drug crisis will be traded for a new prescription drug crisis and nearly three quarters (72%) worry that chronic pain patients will turn to illicit drugs if they do not have access to prescription opioids, according to a new Health Trends™ report from Quest Diagnostics (NYSE: DGX). Seventy percent of primary care physicians wish they had more training on how to taper their patients off opioids.

Continue Reading

Related Documents

Quest Diagnostics Health Trends: Drug Misuse in America 2019. Physician Perspectives and Diagnostic Insights on the Evolving Drug Crisis.
View PDF
Quest Diagnostics Health Trends: Drug Misuse in America 2019. Physician Perspectives and Diagnostic Insights on the Evolving Drug Crisis.

The new report, "Drug Misuse in America 2019: Physician Perspectives and Diagnostics Insights on the Evolving Drug Crisis," provides novel insights into physicians' concerns about patient misuse of prescription and other drugs, as compared with results of objective lab data: half of test results of patients prescribed an opioid or other controlled medication (51%) show signs of drug misuse and one in four (24%) show signs of potentially dangerous drug mixing.

The first-of-its kind report includes findings from a new online survey of 500 U.S. primary care physicians, conducted by The Harris Poll, and commissioned by Quest Diagnostics in consultation with Center on Addiction, about the use of controlled prescribed medications, such as opioids, amphetamines, and benzodiazepines, and illicit drugs. It juxtaposes the survey responses with an analysis of more than 4.4 million de-identified aggregated drug monitoring test results ordered by physicians for patients prescribed controlled medications and performed by Quest Diagnostics between 2011 and 2018.

The intersection of these two data sets reveals, for the first time, the contrast between physician expectations about patient drug use and the evolution of the drug epidemic and actual patient behavior, as revealed by objective lab data, amid a national drug crisis that claimed an estimated 68,500 lives last year.i

The full report is available at www.QuestPDMReport.com

"Quest Diagnostics undertook this research so that we could provide insights into the evolving drug crisis and the potential role of physicians' perspectives about their patients in drug misuse and use disorders," said report co-author Harvey W. Kaufman, M.D., Senior Medical Director and Director, Health Trends Research Program, Quest Diagnostics. "We found that primary care physicians, who are on the front lines of the drug epidemic, are well-intentioned but under-prepared and may miss some of the drug misuse risks affecting their patients, as reflected by our nationally representative laboratory data."

Among the key findings:

Physicians may be overconfident in their ability to recognize prescription drug misuse:

  • One in two patient test results (51%) showed misuse of a controlled medication or other drugs in 2018, a rate that is virtually unchanged from a misuse rate of 52% in 2017 and 2016. Yet, 72% of physicians trust their patients to take their controlled substances as prescribed.
  • Nearly all physicians (95%) feel confident in their ability to discuss risks of prescription drug misuse with patients, but only 55% said they actually discussed potential misuse with most of their patients who were prescribed controlled substances in the past month.

Drug mixing, the most prevalent form of drug misuse, is underestimated by physicians:

  • Most physicians (53%) believe that less than 20% of patients misuse their controlled substances through drug mixing. However, 24% of all patient test results in 2018 showed signs of combining prescription medications with other non-prescribed drugs or substances, including illicit drugs.
  • Drug combining involving fentanyl is also prevalent. Among patient test results that were positive for heroin, 64% were positive for non-prescribed fentanyl. Among patient test results that were positive for cocaine, 24% were positive for non-prescribed fentanyl. The company's testing detects prescription forms of fentanyl, not illicitly manufactured fentanyl, so it is possible actual rates of fentanyl drug combining are even higher.

Gabapentin is emerging as an alternative pain therapy to opioids — just as misuse increases:

  • 78% of physicians say that in an effort to avoid prescribing opioids for the treatment of chronic pain, they often prescribe gabapentin to their patients.
  • Laboratory data show a 40% increase in non-prescribed gabapentin misuse in just the past year, with 13.4% of patient results showing this type of misuse -- making gabapentin the most commonly detected non-prescribed controlled medication in 2018.

Gabapentin, an anticonvulsant that can be used to relieve neuropathic pain, has recently been classified as a controlled substance in some states.

"A vast majority of physicians recognize the need for more tools to prevent opioid drug misuse and substance use disorders, and that is why many are tightening opioid prescribing and turning to gabapentin as an alternative," said report co-author and practicing pain specialist Jeffrey Gudin, M.D., Senior Medical Advisor, Prescription Drug Monitoring, Quest Diagnostics. "While gabapentin may not have opioids' addictive potential, it can exaggerate euphoric effects when combined with opioids or anxiety medications. This drug mixing is dangerous."

Physicians call for more education to combat crisis, cite role of stigma in patient care

Many physicians have called for additional training and education regarding substance use disorders. At least 7 out of 10 physicians would like more information on how to monitor for prescription drug addiction (76%), wish they had more training on what to do if a patient shows signs of addiction (75%) or wish they had more training on how to taper their patients off opioids (70%). A full 88% say prescription drug monitoring (involving laboratory testing) is critical to helping identify patients who may be misusing prescription drugs and 92% believe prescription drug monitoring will increasingly become the standard of care when prescribing controlled substances, although some worry about offending patients (33%).

In addition, 77% of physicians say they believe the stigma surrounding prescription drug addiction impairs patient care.

"The results of this national survey, combined with Quest's data, confirm the need to ensure physicians are equipped to recognize and treat addiction among their patients. Given the frequency of misuse, this issue is clearly more widespread than people think," said Creighton Drury, Chief Executive Officer, Center on Addiction.

Methodology
The Health Trends report involves an analysis of nationally representative de-identified laboratory data based on testing performed by Quest Diagnostics. It also involves an online survey conducted by The Harris Poll on behalf of Quest Diagnostics and Center on Addiction between July 31–August 16, 2019 among 500 physicians who specialize in family practice, general practice, or internal medicine and are licensed in the state where they practice. Results were weighted for years in practice by gender and region to align them with their actual proportions in the population. The report's methodology, including strengths and limitations, is described in the report, which is available for download at www.QuestPDMReport.com.

About Quest Diagnostics Health Trends™
Quest Diagnostics Health Trends™ is a series of scientific reports that provide insights into health topics, based on analysis of objective clinical laboratory data, to empower better patient care, population health management and public health policy. The reports are based on the Quest Diagnostics database of 48 billion de-identified laboratory test results, believed to be the largest of its kind in healthcare. Health Trends has yielded novel insights to aid the management of allergies and asthma, prescription drug monitoring, diabetes, Lyme disease, heart disease, influenza and workplace wellness. Quest Diagnostics also produces the Drug Testing Index (DTI)™, a series of reports on national workplace drug positivity trends based on the company's employer workplace drug testing data. www.QuestDiagnostics.com/HealthTrends

About Center on Addiction
Center on Addiction merged with Partnership for Drug-Free Kids in January 2019 and is the nation's leading science-based nonprofit dedicated to transforming how the nation addresses addiction. We empower families to support loved ones, advance effective addiction care and shape public policies that prevent and treat addiction as a public health issue. Center on Addiction is the only national organization committed to supporting the whole family as it addresses every aspect of substance use and addiction, from prevention to recovery. For more information, visit centeronaddiction.org.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com

i Ahmad FB, Escobedo LA, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2019.

SOURCE Quest Diagnostics

Related Links

http://www.questdiagnostics.com

Modal title

Also from this source

QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023

QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023


Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization

Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Pharmaceuticals
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.